Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Apr 2;15(4):447-448.
doi: 10.1021/acsmedchemlett.4c00119. eCollection 2024 Apr 11.

Novel Isoxazolidines as RIPK1 Inhibitors for Treating Alzheimer's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis

Ram W Sabnis  1
Affiliations
Editorial

Novel Isoxazolidines as RIPK1 Inhibitors for Treating Alzheimer's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis

Ram W Sabnis. ACS Med Chem Lett. .

Abstract

Provided herein are novel isoxazolidines as RIPK1 inhibitors, pharmaceutical compositions, use of such compounds in treating Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS), and processes for preparing such compounds.

PubMed Disclaimer

Conflict of interest statement

The author declares no competing financial interest.

Similar articles

See all similar articles

Cited by

References

    1. Bai Y.; Qiao Y.; Li M.; Yang W.; Chen H.; Wu Y.; Zhang H. RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development. Eur. J. Med. Chem. 2024, 265, 116123.10.1016/j.ejmech.2024.116123. - DOI - PubMed
    1. Regoni M.; Valtorta F.; Sassone J. Dopaminergic neuronal death via necroptosis in Parkinson’s disease: A review of the literature. Eur. J. Neurosci. 2024, 59, 1079–1098. 10.1111/ejn.16136. - DOI - PubMed
    1. Pandeya A.; Kanneganti T.-D. Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes. Trends Mol. Med. 2024, 30, 74–88. 10.1016/j.molmed.2023.10.001. - DOI - PMC - PubMed
    1. Pati S.; Singh Gautam A.; Dey M.; Tiwari A.; Kumar Singh R. Molecular and functional characteristics of receptor-interacting protein kinase 1 (RIPK1) and its therapeutic potential in Alzheimer’s disease. Drug. Discov. Today 2023, 28, 103750.10.1016/j.drudis.2023.103750. - DOI - PubMed
    1. Sabnis R. W. Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases. ACS Med. Chem. Lett. 2024, 15, 177–178. 10.1021/acsmedchemlett.4c00011. - DOI - PMC - PubMed

Publication types

LinkOut - more resources